News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Veristat, Inc. And Karyopharm Therapeutics (KPTI) Enter Into Preferred Provider Agreement For Oncology And Novel Therapeutic Advancement


6/16/2014 10:27:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HOLLISTON, Mass.--(BUSINESS WIRE)--Veristat, a full service Contract Research Organization, announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a Preferred Provider agreement with Veristat.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES